Sionna Therapeutics plans Phase 2a AscenSION CF trial of SION-451 plus SION-2222 in F508del cystic fibrosis adults

PUBT · 2d ago
Sionna Therapeutics plans Phase 2a AscenSION CF trial of SION-451 plus SION-2222 in F508del cystic fibrosis adults
  • Sionna Therapeutics flagged new clinical and preclinical cystic fibrosis data scheduled for presentation at the 2026 North American Cystic Fibrosis Conference.
  • Previously disclosed clinical analyses supported moving beyond an earlier study that missed its main activity endpoint due to adherence and drug-interaction issues.
  • The company plans to advance an oral two-drug regimen into the AscenSION CF Phase 2a proof-of-concept trial in adults with F508del cystic fibrosis.
  • The open-label, 28-day study is expected to start in the first quarter of 2027, focusing on sweat chloride, safety, and pharmacokinetics.
  • New preclinical results pointed to broader potential for NBD1 stabilizer-based combinations across key genotype groups, supporting expansion beyond the initial population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081630PRIMZONEFULLFEED9840912) on October 08, 2026, and is solely responsible for the information contained therein.